Minerva Neurosciences(NERV)

Focus: Minerva Neurosciences is a public biotech company focused on CNS treatments, particularly for neurological and psychiatric disorders. The company operates at a pre-revenue or minimal-revenue stage with a lean R&D footprint.

Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Minerva Neurosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Minerva Neurosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

Roluperidone 64 mg

Negative Symptoms in Schizophrenia

Phase 1

Clinical Trials (1)

NCT06107803A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Phase 1

Help build intelligence for Minerva Neurosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline focused on high-unmet-need CNS indications (schizophrenia, depression) with multiple Phase 1/2 programs
Public company status provides equity upside potential and access to capital markets without venture-stage instability
Burlington, MA location offers proximity to Boston biotech ecosystem with competitive talent markets

Watch Out For

Zero active job openings and severely constrained headcount signal minimal hiring velocity or potential restructuring
Cash burn of $30M in FY2024 with only $21M cash remaining (FY2025) indicates 6-9 month runway without financing—acute liquidity pressure
No marketed products, zero publications, and early-phase pipeline (4x Phase 1, 1x Phase 2, 1x Phase 3) mean years to any clinical validation or revenue inflection

Generated by Claude from Minerva Neurosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

MIN-101

Schizophrenia

Phase 1

Clinical Trials (1)

NCT02232529Pharmacokinetic Study of MIN-101 in Healthy Subjects

Phase 1

MIN-101

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03038646A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Phase 1

MIN-101

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03072056A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

Phase 1

MIN-117 5.0 mg

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT03446846A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Phase 2

Placebo Oral Tablet

Negative Symptoms of Schizophrenia

Phase 3

Clinical Trials (1)

NCT03397134Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Neurology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

3 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$12M6%

Net Income

$1M

Cash

$21M

Source: SEC 10-K Filing